SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

Information to be included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2

Under the Securities Exchange Act of 1934

(Amendment No.     )*

Entellus Medical, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

29363K 105

(CUSIP Number)

December 31, 2015

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 7

SCHEDULE 13G

CUSIP No. 29363K 105 Page 2 of 7 Pages

(1)	Names of reporting persons Medtronic plc
(2)	Check the appropriate box if a member of a group (see instructions)* (a)  ¨        (b)  ¨
(3)	SEC use only
(4)	Citizenship or place of organization     Ireland
Number of shares beneficially owned by each reporting person with		(5)	Sole voting power     956,926
		(6)	Shared voting power     0
		(7)	Sole dispositive power     956,926
		(8)	Shared dispositive power     0
(9)	Aggregate amount beneficially owned by each reporting person     956,926
(10)	Check if the aggregate amount in Row (9) excludes certain shares (see instructions)    ¨
(11)	Percent of class represented by amount in Row (9)     5.1% (1)
(12)	Type of reporting person (see instructions)     OO

(1) The percentage is based upon 18,788,325 shares of common stock outstanding as reported on the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission on November 6, 2015.

Page 2 of 7

SCHEDULE 13G

CUSIP No. 29363K 105 Page 3 of 7 Pages

(1)	Names of reporting persons Covidien Group S.a.r.l.
(2)	Check the appropriate box if a member of a group (see instructions)* (a)  ¨        (b)  ¨
(3)	SEC use only
(4)	Citizenship or place of organization     Luxembourg
Number of shares beneficially owned by each reporting person with		(5)	Sole voting power     956,926 (1)
		(6)	Shared voting power     0
		(7)	Sole dispositive power     956,926 (1)
		(8)	Shared dispositive power     0
(9)	Aggregate amount beneficially owned by each reporting person     956,926 (1)
(10)	Check if the aggregate amount in Row (9) excludes certain shares (see instructions)    ¨
(11)	Percent of class represented by amount in Row (9)     5.1% (2)
(12)	Type of reporting person (see instructions)     OO

(1) The percentage is based upon 18,788,325 shares of common stock outstanding as reported on the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission on November 6, 2015.

Page 3 of 7

Item 1(a) Name of Issuer:

Entellus Medical, Inc.

Item 1(b) Address of Issuer’s Principal Executive Offices:

3600 Holly Lane North, Suite 40

Plymouth, Minnesota 55447

Item 2(a) Name of Persons Filing:

Medtronic plc

Covidien Group S.a.r.l.

Item 2(b) Address of Principal Business Office or, if None, Residence:

Medtronic plc: 20 Lower Hatch Street, Dublin 2, Ireland

Covidien Group S.a.r.l.: 3b, Bd. Prince Henri, 4th Floor L-1724 Luxembourg

Item 2(c) Citizenship:

Medtronic plc: Ireland

Covidien Group S.a.r.l.: Luxembourg

Item 2(d) Title of Class of Securities:

Common Stock.

Item 2(e) CUSIP Number:

29363K 105

Item 3 If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	¨	Broker or dealer registered under Section 15 of the Act.
(b)	¨	Bank as defined in Section 3(a)(6) of the Act.
(c)	¨	Insurance company as defined in Section 3(a)(19) of the Act.
(d)	¨	Investment company registered under Section 8 of the Investment Company Act of 1940.
(e)	¨	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).
(f)	¨	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F).
(g)	¨	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

Page 4 of 7

(i)	¨	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
(j)	¨	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k)	¨	Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4 Ownership

See Cover Pages, Items 5 through 11.

Item 5 Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following    ¨.

Item 6 Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not applicable.

Item 8 Identification and Classification of Members of the Group:

Not applicable.

Item 9 Notice of Dissolution of Group:

Not applicable.

Item 10 Certifications:

Not applicable.

Exhibits Joint Filing Agreement, dated February 16, 2016, between Medtronic plc and Covidien Group, S.a.r.l.

Page 5 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 16, 2016	Medtronic plc
	/s/ Gary Ellis
	Name:	Gary Ellis
	Title:	Executive Vice President and Chief Financial Officer
Dated: February 16, 2016	Covidien Group S.a.r.l.
	/s/ Michelangelo Stefani
	Name:	Michelangelo Stefani
	Title:	General Manager

Page 6 of 7

Joint Filing Agreement

The undersigned hereby agree to file a joint Schedule 13G and any future amendments thereto filed hereafter with respect to the interests of the undersigned in GI Dynamics, Inc. The Schedule 13G to which this Exhibit is attached has been filed on behalf of each of the undersigned and any future amendments thereto filed hereafter shall be filed on behalf of each of the undersigned.

Dated: February 16, 2016	Medtronic plc
	/s/ Gary Ellis
	Name:	Gary Ellis
	Title:	Executive Vice President and Chief Financial Officer
Dated: February 16, 2016	Covidien Group S.a.r.l.
	/s/ Michelangelo Stefani
	Name:	Michelangelo Stefani
	Title:	General Manager

Page 7 of 7